Latest filing published 14 Apr 2026 for Bioventus Inc., €33k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Anthony D'Adamio in Bioventus Inc., where the filings describe the role as chief executive. Between 10 February 2022 and 10 April 2026, the trades on record add up to 24 filings.
No open-market purchase appears, only 8 sales worth €266k. Besides market trades, the filings include 1 share grant and 15 option exercises.
The latest filing, published on 14 April 2026, reports a share grant of €33k in Bioventus Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations